Startseite

Kongressberichte & Archiv

Archiv 2018

SABCS - 41st Annual San Antonio Breast Cancer Symposium

Interviews - Breast Cancer

Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München

Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München

Brustkrebs: Vermeidung von Über- und/oder Untertherapie

News

HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

01-03-2021 18:14
«Wir wollen den Hämato-Onkologischen Patienten eine Stimme geben»

« Nous voulons donner une voix aux patients d’hémato-oncologie »
Weiterlesen ...
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

08-02-2021 10:02
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO
NEU für Patienten mit Morbus Waldenström: Imbruvica® mit Rituximab kombiniert zugelassen - NOUVEAU pour les patients atteints de macroglobulinémie de Waldenström: Autorisation de l’association d’IMBRUVICA® et de rituximab.

04-01-2021 11:31
Weiterlesen ...
Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy

18-12-2020 10:29
The low probability of SARS-CoV-2 infection among these patients (<1%) supports the continuation of most oncologic treatments in the adjuvant and metastatic setting. Based on the present data, delaying active antitumor treatment to avoid SARS-CoV-2 transmission should not be routinely recommended.
Weiterlesen ...
Idecabtagene Vicleucel Leads to High Response Rates in Relapsed/Refractory Myeloma

17-12-2020 13:22
Weiterlesen ...
Adding Venetoclax to Cladribine and Cytarabine Backbone Improves Response Rates, Outcomes in Older Patients With AML

17-12-2020 13:17
Weiterlesen ...
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

03-11-2020 14:22
See abstract @ N Engl J Med 383:1613, October 22, 2020
Colorectal cancer treatment: the winning combinations

07-10-2020 09:43
Read more about optimised combination of anticancer drugs developed by scientists from UNIGE and HUG
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

22-09-2020 08:28
Weiterlesen ...

Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München

Brustkrebs: Vermeidung von Über- und/oder Untertherapie

News

HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

NEU für Patienten mit Morbus Waldenström: Imbruvica® mit Rituximab kombiniert zugelassen - NOUVEAU pour les patients atteints de macroglobulinémie de Waldenström: Autorisation de l’association d’IMBRUVICA® et de rituximab.

Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy

Idecabtagene Vicleucel Leads to High Response Rates in Relapsed/Refractory Myeloma

Adding Venetoclax to Cladribine and Cytarabine Backbone Improves Response Rates, Outcomes in Older Patients With AML

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Colorectal cancer treatment: the winning combinations

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Newsletter